Antibody therapy for modulating function of intestinal receptors and methods of treating diabetes and obesity
The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition.
1. A pharmaceutically acceptable composition comprising an antibody specific for a target apical intestinal receptor in the gastrointestinal tract of a patient formulated for direct delivery to the gastrointestinal (GI) tract of the patient wherein the antibody is derived from the milk or colostrum of a ruminant animal and wherein the antibody modulates at least one biological function of the target apical intestinal receptor.
2. The composition of claim 1 , wherein the antibody is a polyclonal antibody isolated from milk or colostrum.
3. The composition of claim 1 , wherein the ruminant is a cow.
4. A method of treating diabetes or obesity in a patient comprising orally administering a therapeutically effective amount of the composition of claim 1 to the patient wherein the antibody is specific for a sugar receptor.
5. The method of claim 4 , wherein the composition is administered before ingesting a substance that may contain glucose or concurrently with the ingestion of a substance that may contain glucose, fructose or a related hexose.
6. The method of claim 4 , wherein the composition is administered after ingesting a substance that may contain glucose, fructose or a related hexose.